PodParley PodParley
Let's Talk Risk! with Dr. Naveen Agarwal

Let's Talk Risk! with Dr. Naveen Agarwal

Bookmark

Let's Talk Risk! with Dr. Naveen Agarwal is a technology podcast hosted by Casual and informal conversations about practical aspects of medical device risk management.. It has 161 episodes, with the latest published April 2026.

Every Friday, Dr. Naveen Agarwal leads a Let's Talk Risk! conversation with industry colleagues to discuss practical challenges and share best practices in risk management. In the highly regulated world of medical devices, most practitioners struggle with the "how" of risk management. Regulatory requirements are complex, confusing and ever changing. Establishing an effective risk management process that satisfies the scrutiny of regulators and auditors without creating barriers to innovation is a significant challenge in the industry. Dr. Agarwal believes that no single "expert" has all the answers, and it is only when we connect, share and learn from each other that we all become better. Let us keep learning together! naveenagarwalphd.substack.com

technology ·en ·161 episodes

#
Title
1

Case Study: How Patient Preference Data Rescued a High-Risk Device

2

LTR 150: Jonathan Kendler on Rethinking Human Factors Engineering for AI/ML-Enabled Devices

3

LTR 149: Lavanya Ramnath on Risk Analysis, IDE Strategy, and Patient-Centered Design

4

LTR 148: Chris Daly on Companion Diagnostics, AI, and FDA’s Evolving Approach

5

LTR 147: Richard Matt on Bringing Benefit–Risk Upstream in Design and Development

6

LTR 146: Ganesh Sabat on Scaling MedTech Through Quality

7

LTR 145: Holly Cotter on Avoiding the QMSR Scramble with Smart Quality Planning

8

LTR 144: Jean Blom on How Hazard-First Thinking Improves Risk Management

9

LTR 143: Jennifer Mascioli-Tudor on Leading Proactive Quality in the QMSR Era

10

LTR 142: Florian Tolkmitt on Clinical Evaluation, Risk, and the New ISO Draft Standard

11

LTR 141: Ashkon Rasooli on Applying an Agile Mindset to Risk-Based Quality Systems Under QMSR

12

LTR 140: Pujitha Gourabathini on Connecting Risk Management and Design Controls

13

LTR 139: Steve Silverman on FDA Readiness for QMSR

14

LTR 138: Michelle Lott on QMSR Readiness, Risk-Based Assurance and FDA Expectations

15

LTR 137: Priya Setty on QMSR, Risk-Based Assurance, and Building a Future-Ready RA Career

16

LTR 136: Adam Isaacs Rae on What QMSR Really Changes and What It Doesn't

17

LTR 135: Allison Komiyama on Rethinking Benefit-Risk in MedTech

18

LTR 134: James Pink on Responsible AI and Future of MedTech Safety

19

LTR 133: Megan Kane on Leading QMSR Readiness in MedTech Startups

20

LTR 132: Bijan Elahi on Future of MedTech Safety and the 2026 Conference in Boston

21

LTR 131: Rick Wedge on the Human Side of Safety Risk Management

22

LTR 130: Hannah Walter on Human Factors and Inclusive Design in Medical Devices

23

LTR 129: Viral Thakkar on breakthrough innovation and the Lungpacer story

24

Case Study: The WATCHMAN TruSeal Recall and the Hidden Risk of Procedural Variation

25

LTR 128: Edward Ball on AI, Vigilance and Future of MedTech Regulation

26

LTR 127: Ajay Dankar on Proactive AI Governance in MedTech

27

FDA CSA Debate: Streamlined Assurance or Audit Ambiguity?

28

LTR 126: Adam Foresman on Proactive Compliance and Future of MedTech

29

LTR 125: Kevin Schawinski on Building Trustworthy AI and MedTech Readiness

30

Case Study: Comparing EU and FDA Cybersecurity Guidance for Medical Devices

31

LTR 124: Omar Al Kalaa on Wireless Coexistence and Risk in Connected Medical Devices

32

LTR 123: Richard Matt on Effective Risk Communication

33

Case Study: What AI/ML Device Recalls Reveal About Emerging Risks

34

LTR 122: Tibor Zechmeister on PSUR Best Practices

35

LTR 121: Michelle Lott on Risk, CAPA and FDA Inspections under QMSR

36

Case Study: Contrasting U.S. and EU Approaches to AI Regulation

37

LTR 120: Atty Chakraborty on India's Rising MedTech Sector

38

LTR 119: AI, Risk and Regulatory Strategy with Dr. Jay Vaishnav

39

Case Study: When Clues to a Future Recall Hide in Plain Sight

40

LTR 118: Off-Label Use with Kristen Petersen

41

LTR 117: Queenita Fernandes on Smart Use of AI for Clinical Evaluation

42

A Quick Primer on FDA's Final Guidance for Cybersecurity in Medical Devices

43

LTR 116: Priyanka Murawala on ISO 10993 Update, Biocompatibility, Learning from Recalls

44

LTR 115: Startup Lessons from EU MedTech Shark Tank

45

LTR 114: What QA/RA Professionals Need to Know About Rapidly Growing MedTech in India

46

Case Study: When Underestimating Risk Leads to a Warning Letter

47

LTR 113: Highlights from the International Medical Device Safety Risk Management Conference

48

LTR 112: Overcoming organizational barriers to risk management through collaboration

49

LTR 111: How to sustain and grow a community of practice in risk management

50

Case Study: A Warning Letter Exposes Issues in Risk Analysis

URL copied to clipboard!